Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Celularity Inc. (NASDAQ:CELU – Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 20,333 shares of the company’s stock, valued at approximately $26,000.
A number of other institutional investors also recently made changes to their positions in the business. Citigroup Inc. bought a new position in Celularity in the 1st quarter worth $36,000. American International Group Inc. bought a new stake in Celularity during the 2nd quarter valued at about $25,000. JPMorgan Chase & Co. bought a new stake in Celularity during the 2nd quarter valued at about $28,000. Legal & General Group Plc bought a new stake in Celularity during the 2nd quarter valued at about $29,000. Finally, UBS Group AG increased its stake in Celularity by 177.6% during the 2nd quarter. UBS Group AG now owns 10,300 shares of the company’s stock valued at $36,000 after purchasing an additional 6,590 shares in the last quarter. Hedge funds and other institutional investors own 24.19% of the company’s stock.
Celularity Stock Performance
Shares of NASDAQ CELU opened at $0.50 on Friday. Celularity Inc. has a one year low of $0.40 and a one year high of $11.14. The firm has a market cap of $83.13 million, a PE ratio of -3.15 and a beta of 0.20. The firm has a fifty day moving average of $0.62 and a 200 day moving average of $1.08.
Analyst Ratings Changes
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
- Get a free copy of the StockNews.com research report on Celularity (CELU)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.